Avinger Hires Chief Financial Officer

Avinger Inc., a developer of treatments for peripheral artery disease (PAD), has hired Mark Weinswig as chief financial officer (CFO). Weinswig succeeds Matt Ferguson, who will be leaving the company to pursue other opportunities.
 
Ferguson remains a full-time employee of Avinger until Aug. 1, and will continue as a consultant through Dec. 31 to ensure a smooth transition.
 
“We are excited to welcome Mark Weinswig to our executive leadership team,” said Jeff Soinski, Avinger’s president and CEO. “Mark’s extensive experience in driving operational and financial improvements is a great fit as we launch our new products, execute against our commercial plan and continue to strengthen our organization.
 
Weinswig brings extensive strategic and operational financial experience to Avinger, including almost 20 years in financial leadership positions in private and publicly-traded technology companies. Weinswig previously served as the CFO of Emcore, One Workplace, and Aqua Metals. Earlier in his career, he was International Financial Controller for Coherent, and held senior financial positions at Oclaro. Weinswig began his career in public accounting at PricewaterhouseCoopers and worked at Morgan Stanley as an equity research analyst. He has held both certified public accountant and chartered financial analyst designations, and has an M.B.A. from Santa Clara University and a bachelor of science degree in accounting from Indiana University.
 
“We appreciate the many contributions Matt Ferguson has made to Avinger and his critical role in financing the development and commercialization of our Lumivascular technology,” Soinski said. “I’m glad Matt will continue to be involved with the company through the end of the year on a transitional basis, and wish him all the best in his future endeavors.”
 
Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system to diagnose and treat patients with peripheral artery disease. Avinger aims to change the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion catheters, and the Pantheris family of atherectomy devices. Avinger is based in Redwood City, Calif.